Business ❯ Pharmaceuticals ❯ Drug Development

Obesity Treatments

Novo Nordisk Licensing Deals Pfizer Revenue Growth Strategies Acquisitions Viking Therapeutics GLP-1 Agonists Metsera AstraZeneca Wegovy Pill Wegovy CagriSema GLP-1 Drugs Petrelintide

Eli Lilly Builds $1.5 Billion Stockpile of Orforglipron as FDA Decision Nears

The $1.5 billion pre‑launch cache signals a bid to avoid past GLP‑1 supply gaps ahead of an expected spring FDA ruling on the once‑daily pill.

Eli Lilly Tightens GLP-1 Grip, Guides Up to $83 Billion for 2026

AstraZeneca Strikes $1.2 Billion CSPC Pact for Once‑Monthly Obesity and Diabetes Programs

Pfizer Licenses Early-Stage Oral GLP-1 From YaoPharma in Up to $2 Billion Deal

Pfizer Closes Metsera Buyout, Adding GLP-1 Assets in Cash-Plus-CVR Deal

Eli Lilly to Acquire Verve Therapeutics for $1.3 Billion